Your activity: 2 p.v.

Finasteride: Drug information

Finasteride: Drug information
(For additional information see "Finasteride: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Propecia;
  • Proscar
Brand Names: Canada
  • ACH-Finasteride;
  • ACT Finasteride [DSC];
  • AG-Finasteride;
  • APO-Finasteride;
  • Auro-Finasteride;
  • DOM-Finasteride;
  • JAMP-Finasteride;
  • M-Finasteride;
  • MINT-Finasteride;
  • PMS-Finasteride;
  • Propecia;
  • Proscar;
  • RAN-Finasteride [DSC];
  • RIVA-Finasteride;
  • SANDOZ Finasteride;
  • SANDOZ Finasteride A;
  • TEVA-Finasteride;
  • VAN-Finasteride [DSC]
Pharmacologic Category
  • 5 Alpha-Reductase Inhibitor
Dosing: Adult
Androgenetic alopecia

Androgenetic alopecia (male pattern hair loss): Males: Oral: 1 mg once daily. Continue for at least 12 months to assess full effect; continued daily use is required to sustain benefit (Ref).

Benign prostatic hyperplasia

Benign prostatic hyperplasia (alternative agent): Note: Reserve use for patients with significantly enlarged prostates (prostate volume >30 mL, prostate-specific antigen >1.5 ng/dL, or palpable prostate enlargement on digital rectal exam) or those with hematuria associated with benign prostatic hyperplasia (Ref).

Oral: 5 mg once daily (either as a single agent or in combination with an alpha-1 adrenergic antagonist); 6 to 12 months of treatment is usually needed to improve symptoms (Ref).

Hirsutism

Hirsutism (alternative agent) (off-label use): Note: Typically given in addition to oral contraceptives (OCs) if inadequate response to OCs is observed after 6 months. May be considered as initial therapy for females who cannot conceive or who are using reliable contraception.

Females: Oral: 2.5 to 5 mg once daily. Assess response at 6-month intervals before adjusting dose, adding additional agents, or switching to alternative therapy (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: Mild to severe impairment: No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be dialyzed (highly protein bound, moderate Vd): No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Unlikely to be dialyzed (highly protein bound, moderate Vd): No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution (finasteride is metabolized extensively in the liver)

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Propecia: 1 mg

Proscar: 5 mg [contains fd&c blue #2 (indigo carm) aluminum lake]

Generic: 1 mg, 5 mg

Generic Equivalent Available: US

Yes

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Propecia: 1 mg

Proscar: 5 mg [contains corn starch, fd&c blue #2 (indigo carm) aluminum lake]

Generic: 1 mg, 5 mg

Administration: Adult

Oral: May be administered with or without meals. Pregnant patients and patients who could become pregnant should not touch or handle crushed or broken tablets.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 3]).

Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).

Use: Labeled Indications

Androgenetic alopecia (male pattern hair loss): Treatment of male pattern hair loss in men.

Limitations of use: Efficacy in bitemporal recession has not been established.

Benign prostatic hyperplasia: Treatment (monotherapy) of symptomatic benign prostatic hyperplasia (BPH) to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of need for BPH-related surgery; used in combination with an alpha-1 adrenergic antagonist to reduce the risk of symptomatic progression.

Limitations of use: Not approved for the prevention of prostate cancer.

Use: Off-Label: Adult

Hirsutism

Medication Safety Issues
Sound-alike/look-alike issues:

Finasteride may be confused with dutasteride, furosemide

Proscar may be confused with Prograf, ProSom, Provera, PROzac

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.

Adverse Reactions (Significant): Considerations
Sexual dysfunction

Finasteride may cause sexual dysfunction, including impotence, decreased libido, ejaculatory disorder, and sexual disorder (Ref), which may persist after discontinuation (Ref). Of note, it has been hypothesized that persistent sexual dysfunction may contribute to psychological adverse reactions (eg, anxiety and depression) and suicidal ideation and suicidal tendencies in younger patients treated for alopecia (Ref).

Mechanism: Dose and time-related; may be related to antiandrogenic effects and subsequent decreased nitric oxide in the corpus cavernosum (Ref).

Onset: Delayed; may begin after ~6 months of therapy and peak during the first year (Ref).

Risk factors:

• Independent risk factors include older patients and benign prostatic hyperplasia (Ref)

• Higher dosage of finasteride (5 mg/day) (Ref)

• Length of therapy ≥1 year (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%: Genitourinary: Impotence (5% to 19%) (table 1)

Finasteride: Adverse Reaction: Impotence

Drug (Finasteride)

Placebo

Dose

Indication

Number of Patients (Finasteride)

Number of Patients (Placebo)

Comments

19%

12%

5 mg per day

BPH

768

737

N/A

8%

4%

N/A

BPH

1524

1516

Year 1

5%

5%

N/A

BPH

1524

1516

Years 2 to 4

1% to 10%:

Cardiovascular: Hypotension (1%), orthostatic hypotension (9%) (table 2), peripheral edema (1%)

Finasteride: Adverse Reaction: Orthostatic Hypotension

Drug (Finasteride)

Placebo

Dose

Indication

Number of Patients (Finasteride)

Number of Patients (Placebo)

9%

8%

5 mg/day

BPH

768

737

Endocrine & metabolic: Decreased libido (2% to 10%) (table 3), gynecomastia (1% to 2%)

Finasteride: Adverse Reaction: Decreased Libido

Drug (Finasteride)

Placebo

Dose

Indication

Number of Patients (Finasteride)

Number of Patients (Placebo)

Comments

10%

6%

5 mg/day

BPH

768

737

N/A

6%

3%

N/A

BPH

1524

1516

Year 1

3%

3%

N/A

BPH

1524

1516

Years 2 to 4

2%

1%

1 mg/day

Male pattern hair loss

945

934

N/A

Genitourinary: Breast tenderness (≤1%), decreased ejaculate volume (2% to 4%), ejaculatory disorder (≤7%) (table 4), prostate cancer - high grade (2%) (Thompson 2003, Thompson 2013), sexual disorder (3%) (table 5)

Finasteride: Adverse Reaction: Ejaculatory Disorder

Drug (Finasteride)

Placebo

Dose

Indication

Number of Patients (Finasteride)

Number of Patients (Placebo)

Comments

7%

2%

5 mg/day

BPH

768

737

N/A

0.8%

0.1%

N/A

BPH

1524

1516

Year 1

0.2%

0.1%

N/A

BPH

1524

1516

Years 2 to 4

1%

0.7%

1 mg/day

Male pattern hair loss

945

934

N/A

Finasteride: Adverse Reaction: Sexual Disorder

Drug (Finasteride)

Placebo

Dose

Indication

Number of Patients (Finasteride)

Number of Patients (Placebo)

3%

0.9%

5 mg/day

BPH

768

737

Respiratory: Rhinitis (1%)

<1%: Genitourinary: Malignant neoplasm of the breast (men)

Postmarketing:

Dermatologic: Acute generalized exanthematous pustulosis (T-cell mediated localized exanthematous pustulosis) (Tresch 2011), erythematous rash (erythema annulare centrifugum) (Al Hammadi 2007), fixed drug eruption (Oyama 2009), skin photosensitivity (Yamade 2021), urticaria (Moreno-Fernandez 2010)

Genitourinary: Hemospermia (Fouda 2017), male infertility (temporary) (Chiba 2010; Ricci 2012), testicular pain (Pereira 2020)

Hypersensitivity: Hypersensitivity angiitis (Lear 1996)

Nervous system: Anxiety (Nguyen 2021), depression (may persist after discontinuation) (Nguyen 2021, Welk 2017), suicidal ideation (may persist after discontinuation) (Ali 2015; Nguyen 2021, Welk 2017), suicidal tendencies (may persist after discontinuation) (Nguyen 2021, Welk 2017)

Contraindications

Hypersensitivity to finasteride or any component of the formulation; pregnancy or patients who may potentially be pregnant.

Warnings/Precautions

Disease-related concerns:

• Diminished urinary flow: Carefully monitor patients with a large residual urinary volume or severely diminished urinary flow for obstructive uropathy; these patients may not be candidates for finasteride therapy.

• Hepatic impairment: Use with caution in patients with hepatic impairment; finasteride is extensively metabolized in the liver.

• Prostate cancer: When compared to placebo, 5-alpha-reductase inhibitors (5-ARIs) have been associated with an increase in the incidence of high-grade prostate cancers; 5-ARIs are not approved in the United States or Canada for the prevention of prostate cancer.

Special handling:

• Females: Active ingredient of crushed or broken tablets can be absorbed through the skin; unbroken tablets are coated, which prevents contact with the active ingredient during normal handling. Patients who could become pregnant should not touch or handle crushed or broken tablets.

Other warnings/precautions:

• Appropriate use: Other urological diseases (including prostate cancer) should be ruled out before initiating (in benign prostatic hyperplasia [BPH] management). Not indicated for use in pediatric patients.

• Duration of therapy: For BPH, a minimum of 6 months of treatment may be necessary to determine whether an individual will respond to finasteride; for male pattern hair loss, daily use for ≥3 months may be required before benefit is observed (withdrawal of treatment leads to reversal of hair growth effect within 12 months).

• Prostate specific antigen monitoring: Reduces prostate specific antigen (PSA) concentration by ~50% within 6 months of treatment. Reestablish new PSA baseline after initiation. A confirmed PSA increase while on this medication, even if within normal limits, may be associated with an increased risk for prostate cancer and should be evaluated. Finasteride does not interfere with free PSA levels.

Metabolism/Transport Effects

Substrate of CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

There are no known significant interactions.

Reproductive Considerations

Although use is contraindicated in patients who may potentially be pregnant, finasteride has been evaluated for various indications in premenopausal patients, including the treatment of hirsutism and female pattern hair loss. Adequate contraception is recommended (ACOG 2018; Carmina 2019; ES [Martin 2018]; Hu 2019; Iamsumang 2020). Contraception should be used during treatment and for at least 30 days after the last finasteride dose (Carmina 2019).

Patients who could become pregnant should not touch or handle crushed or broken tablets.

Finasteride is present in semen. Male infertility and poor seminal quality have been reported and may be reversible upon discontinuation of finasteride. Adverse events may be dose related and, less likely, associated with doses used for male pattern hair loss (Zakhem 2019).

Pregnancy Considerations

Based on the mechanism of action and data from animal reproduction studies, in utero exposure to finasteride may lead to abnormal development of the male genital tract. Pregnancy outcome information following inadvertent finasteride exposure during pregnancy is limited (AlSaad 2018). Use is contraindicated during pregnancy.

Pregnant patients are advised to avoid contact with crushed or broken tablets and immediately wash the contact area with soap and water if exposure occurs.

Breastfeeding Considerations

It is not known if finasteride is present in breast milk.

Patients who could become pregnant should not touch or handle crushed or broken tablets.

Monitoring Parameters

To interpret serial prostate-specific antigens (PSAs), establish a new PSA baseline ≥6 months after treatment initiation and monitor PSA periodically thereafter; International Prostate Symptom Score (baseline and 3 to 12 months after treatment initiation); urinalysis (baseline); objective and subjective signs of relief of benign prostatic hyperplasia and lower urinary tract symptoms (AUA [Lerner 2021a; McVary 2022; manufacturer's labeling).

Mechanism of Action

Finasteride competitively inhibits type II 5-alpha reductase, resulting in inhibition of the conversion of testosterone to dihydrotestosterone and markedly suppresses serum dihydrotestosterone levels

Pharmacokinetics

Duration: Dihydrotestosterone levels return to normal within 14 days of discontinuation of treatment; BPH: Prostate volume returns to baseline within ~3 months after discontinuation; Male pattern baldness: Reversal of increased hair count within 12 months

Distribution: Vdss: 76 L

Protein binding: ~90%

Metabolism: Hepatic (extensive) via CYP3A4; two active metabolites (<20% activity of finasteride)

Bioavailability: Mean: 5 mg: ~63%; 1 mg: 65% (not affected by food)

Half-life elimination, serum: 5 to 6 hours (range: 3 to 16 hours); Elderly (≥70 years): 8 hours (range: 6 to 15 hours)

Time to peak, serum: 1 to 2 hours

Excretion: Feces (57%) and urine (39%; as metabolites)

Pharmacokinetics: Additional Considerations

Altered kidney function: Urinary excretion of metabolites was decreased in patients with renal impairment. This decrease was associated with an increase in fecal excretion of metabolites. Plasma concentrations of metabolites were significantly higher in patients with renal impairment (based on a 60% increase in total radioactivity AUC).

Older adult: Mean AUC0-24 increases 15%.

Pricing: US

Tablets (Finasteride Oral)

1 mg (per each): $2.71 - $2.72

5 mg (per each): $0.11 - $3.19

Tablets (Propecia Oral)

1 mg (per each): $4.34

Tablets (Proscar Oral)

5 mg (per each): $5.93

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Alofecid (KR);
  • Alopec (BD);
  • Androfin (LV);
  • Apeplus (CL);
  • Aprodil (EC);
  • Atepros (PH);
  • Bearfina (KR);
  • Benstat (TH);
  • Bibfins (TW);
  • Binfin (SG);
  • Binfin 5 (ZW);
  • Borealis (CR, DO, GT, HN, NI, PA, SV);
  • Caosol (CR, DO, GT, HN, NI, PA, SV);
  • Capyla (BR);
  • Chibro-Proscar (FR);
  • Damocare (HK);
  • Damopecia (KR);
  • Daric (PY);
  • Disprol (MX);
  • Fenryde (ZA);
  • Finapecia (EG);
  • Finapros (PH);
  • Finarid (PH);
  • Finas (BD, SG);
  • Finascar (JO);
  • Finaspros (CO);
  • Finast (LK, VN);
  • Finasta (AU);
  • Finastar (KR);
  • Finastid (HR);
  • Finated (KR);
  • Finatra (CN);
  • Fincar (EG, HK, IN, KR, LK, MY, ZA);
  • Finex (CZ);
  • Finhair (FR);
  • Finide (PH);
  • Finiscar (QA);
  • Finnacar (AU);
  • Finpro (ID, ZA);
  • Finstal-5 (PH);
  • Finster (LV);
  • Fintrid (IE);
  • Firide (TH);
  • Fistrin (CO);
  • Folcres (AR);
  • For-BPH (PH);
  • Fynasid (TW);
  • GPO-Finax (TH);
  • Harifin (TH);
  • Jun Neng (CN);
  • Maxteride (HK);
  • Monastar (KR);
  • Nasterol (VE);
  • Nopecia (EG);
  • Oilpp (NI);
  • Olipp (CR, DO, GT, HN, PA, SV);
  • Penester (LV, UA);
  • Pro-Cure (IL);
  • Proavenir (IL);
  • Profal (IE);
  • Profina (ZA);
  • Prohair (CL, QA);
  • Pronax (PH);
  • Pronor (LK);
  • Propecia (AE, AR, AT, AU, BR, BS, BZ, CH, CN, CO, CY, DE, EC, ES, FI, GB, GR, HK, IL, IS, IT, JM, JP, KW, LB, LU, MT, MY, NL, NZ, PE, PH, PL, RO, SA, SE, SG, TH, TT, TW);
  • Propeshia (MX);
  • Proscar (AE, AR, AT, AU, BB, BD, BE, BG, BH, BM, BO, BR, CH, CL, CN, CR, CY, DE, DK, DO, EC, EE, EG, ES, FI, GB, GR, GT, GY, HK, HN, HR, ID, IE, IT, JO, KR, KW, LB, LU, MT, MX, MY, NI, NO, NZ, PA, PE, PH, PK, PL, PR, PT, RO, RU, SA, SE, SG, SK, SR, SV, TH, TR, TW, VE, VN);
  • Proseride (TH);
  • Prosfin (BD);
  • Prostacare (LB, QA);
  • Prostan (UA);
  • Prostanus (PH);
  • Prostarinol (LV);
  • Prosterid (HU);
  • Prosteride (HK, PH, TH);
  • Prostide (ID);
  • Prostop (UY);
  • Proteside (JO);
  • Prusc (TW);
  • Reprostom (ID);
  • Skarex (KR);
  • Stercia (SG);
  • Stercia-5 (TH);
  • Sterzar (TH);
  • Tealep (CR, DO, GT, HN, NI, PA, SV);
  • Tensen (TW);
  • Uromedin (PY);
  • Zerlon (RU)


For country code abbreviations (show table)
  1. <800> Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.
  2. Al Hammadi A, Asai Y, Patt ML, Sasseville D. Erythema annulare centrifugum secondary to treatment with finasteride. J Drugs Dermatol. 2007;6(4):460-463. [PubMed 17668547]
  3. Ali AK, Heran BS, Etminan M. Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: A pharmacovigilance study. Pharmacotherapy. 2015;35(7):687-95. doi:10.1002/phar.1612 [PubMed 26133534]
  4. AlSaad D, Lee BH, Al-Obaidly S. Finasteride use during pregnancy and early neonatal outcome: a case report. Int J Clin Pharm. 2018;40(4):803-805. doi:10.1007/s11096-018-0661-5 [PubMed 29855987]
  5. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstet Gynecol. 2018;131(6):e157-e171. doi: 10.1097/AOG.0000000000002656. [PubMed 29794677]
  6. Barbieri RL, Chang J. Management of hirsutism in premenopausal women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 29, 2021.
  7. Barrionuevo P, Nabhan M, Altayar O, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2018;103(4):1258-1264. doi: 10.1210/jc.2017-02052. [PubMed 29522176]
  8. Based on expert opinion.
  9. Carmina E, Azziz R, Bergfeld W, et al. Female pattern hair loss and androgen excess: a report from the Multidisciplinary Androgen Excess and PCOS Committee. J Clin Endocrinol Metab. 2019;104(7):2875-2891. doi:10.1210/jc.2018-02548 [PubMed 30785992]
  10. Chiba K, Yamaguchi K, Li F, Ando M, Fujisawa M. Finasteride-associated male infertility. Fertil Steril. 2011;95(5):1786.e9-e11. doi:10.1016/j.fertnstert.2010.12.001 [PubMed 21193189]
  11. Donovan J, Goldstein BG, Goldstein AO. Treatment of androgenetic alopecia in men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 26, 2019.
  12. Fertig RM, Gamret AC, Darwin E, Gaudi S. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Dermatol Online J. 2017;23(11):13030/qt24k8q743 [PubMed 29447628]
  13. Fouda AM, Bazeed AM. Hematuria and hematospermia associated with the use of finasteride for the treatment of androgenic alopecia: a case report. Drug Saf Case Rep. 2017;4(1):14. doi:10.1007/s40800-017-0059-7 [PubMed 29090364]
  14. Gray SL, Semla TP. Post-finasteride syndrome. BMJ. 2019;366:l5047. doi:10.1136/bmj.l5047 [PubMed 31399423]
  15. Hu AC, Chapman LW, Mesinkovska NA. The efficacy and use of finasteride in women: a systematic review. Int J Dermatol. 2019;58(7):759-776. doi:10.1111/ijd.14370 [PubMed 30604525]
  16. Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. Drug Des Devel Ther. 2020;14:951-959. doi:10.2147/DDDT.S240615 [PubMed 32184564]
  17. Kaplan SA, Lee JY, Meehan AG, Kusek JW. Time course of incident adverse experiences associated with doxazosin, finasteride and combination therapy in men with benign prostatic hyperplasia: The MTOPS trial. J Urol. 2016;195(6):1825-1829. doi:10.1016/j.juro.2015.11.065 [PubMed 26678956]
  18. Lear JT, Byrne JP. Finasteride-related cutaneous vaculitis. Postgrad Med J. 1996;72(844):127. doi:10.1136/pgmj.72.844.127-a [PubMed 8871471]
  19. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. J Urol. 2021a;206(4):806-817. doi:10.1097/JU.0000000000002183 [PubMed 34384237]
  20. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part II-surgical evaluation and treatment. J Urol. 2021b;206(4):818-826. doi:10.1097/JU.0000000000002184 [PubMed 34384236]
  21. Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999;40(6, pt 1):930-937. doi:10.1016/s0190-9622(99)70081-2. [PubMed 10365924]
  22. Liu L, Zhao S, Li F, et al. Effect of 5α-reductase inhibitors on sexual function: A meta-analysis and systematic review of randomized controlled trials. J Sex Med. 2016;13(9):1297-1310. doi:10.1016/j.jsxm.2016.07.006 [PubMed 27475241]
  23. Maksym RB, Kajdy A, Rabijewski M. Post-finasteride syndrome - does it really exist? Aging Male. 2019;22(4):250-259. doi:10.1080/13685538.2018.1548589 [PubMed 30651009]
  24. Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(4):1233-1257. doi:10.1210/jc.2018-00241. [PubMed 29522147]
  25. McConnell JD, Roehrborn CG, Bautista OM, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398. doi:10.1056/NEJMoa030656. [PubMed 14681504]
  26. McVary KT. Medical treatment of benign prostatic hyperplasia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 23, 2022.
  27. Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99(13):1025-1035. doi:10.1093/jnci/djm023 [PubMed 17596576]
  28. Moreno-Fernandez A, Mira Laguarda JM, Ruiz-Hornillos FJ, Rubio Sotes M. Urticarial rush due to finasteride. Allergy. 2010;65(3):405-406. doi:10.1111/j.1398-9995.2009.02165.x [PubMed 19814757]
  29. Nguyen DD, Marchese M, Cone EB, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 2021;157(1):35-42. doi:10.1001/jamadermatol.2020.3385 [PubMed 33175100]
  30. Oyama N, Kaneko F. Solitary fixed drug eruption caused by finasteride. J Am Acad Dermatol. 2009;60(1):168-169. doi:10.1016/j.jaad.2008.07.037 [PubMed 19103375]
  31. Pereira AFJR, Coelho TOA. Post-finasteride syndrome. An Bras Dermatol. 2020;95(3):271-277. doi:10.1016/j.abd.2020.02.001 [PubMed 32317131]
  32. Propecia (finasteride) [prescribing information]. Whitehouse Station, NJ: Merck & Co; January 2014.
  33. Propecia (finasteride) [prescribing information]. Whitehouse Station, NJ: Merck & Co; July 2022.
  34. Proscar (finasteride) [prescribing information]. Jersey City, NJ: Organon LLC; June 2021.
  35. Refer to manufacturer's labeling.
  36. Ricci G, Martinelli M, Luppi S, et al. Finasteride and fertility: case report and review of the literature. J Drugs Dermatol. 2012;11(12):1511-1513. [PubMed 23377525]
  37. Shin YS, Karna KK, Choi BR, Park JK. Finasteride and erectile dysfunction in patients with benign prostatic hyperplasia or male androgenetic alopecia. World J Mens Health. 2019;37(2):157-165. doi:10.5534/wjmh.180029 [PubMed 30209896]
  38. Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet. 1996;30(1):16-27. doi:10.2165/00003088-199630010-00002 [PubMed 8846625]
  39. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. doi:10.1056/NEJMoa030660. [PubMed 12824459]
  40. Thompson IM Jr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369(7):603-610. doi:10.1056/NEJMoa1215932. [PubMed 23944298]
  41. Tresch S, Cozzio A, Kamarashev J, et al. T cell-mediated acute localized exanthematous pustulosis caused by finasteride. J Allergy Clin Immunol. 2012;129(2):589-594. doi:10.1016/j.jaci.2011.07.033 [PubMed 21868079]
  42. US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf. Updated September 2016. Accessed October 5, 2016.
  43. Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of suicidality and depression with 5α-reductase inhibitors. JAMA Intern Med. 2017;177(5):683-691. doi:10.1001/jamainternmed.2017.0089. [PubMed 28319231]
  44. Wessells H, Roy J, Bannow J, et al; PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003;61(3):579-584. doi:10.1016/s0090-4295(02)02401-9 [PubMed 12639651]
  45. Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999;4(3):282-284. [PubMed 10674382]
  46. Yamada T. Photosensitivity reaction induced by finasteride. J Gen Fam Med. 2021;23(3):185-186. doi: 10.1002/jgf2.510 [PubMed 35509334]
  47. Zakhem GA, Motosko CC, Mu EW, Ho RS. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review. J Am Acad Dermatol. 2019;80(4):957-969. doi:10.1016/j.jaad.2018.09.031 [PubMed 30287313]
Topic 8447 Version 361.0